Molecular Tumor Board

Program Leadership

John Strickler, MD
Matthew McKinney, MD

The Duke Molecular Tumor Board (DMTB) was developed to foster precision medicine within Duke Cancer Institute (DCI).

The molecular tumor board meets once a week and brings together a diverse, multi-disciplinary group of pathologists, oncologists, scientists, and clinical trial coordinators to disseminate insights related to clinical next-generation DNA sequencing performed on oncology samples. This includes discussions of best practices, clinical recommendations based on specific mutational profiles, and referrals to hereditary genetics.

To find out more about DMTB meetings, or request a patient be reviewed, please email Duke Molecular Tumor Board or call Michelle Green, research program leader, 919.681.1904.